Volume Kinetics of Fluid Resuscitation in Early Sepsis

Last updated: March 6, 2025
Sponsor: Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu
Overall Status: Active - Recruiting

Phase

N/A

Condition

Soft Tissue Infections

Treatment

Ringer's Lactate

Clinical Study ID

NCT06499701
17736
  • Ages > 18
  • All Genders

Study Summary

The recommended volume resuscitation for patients with early sepsis-induced hypoperfusion is at least 30 ml/kg of crystalloid administered within the first three hours. However, this standardized approach does not account for individual patient variability and lacks personalization. Additionally, the effects of administering 30 ml/kg on intercompartmental fluid shifts between the plasma and interstitial compartments remain unclear. This study aims to describe the volume kinetics of administering 30 ml/kg of Ringer's Lactate in patients with early sepsis-induced hypoperfusion within the first three hours.

Eligibility Criteria

Inclusion

Inclusion Criteria:

A diagnosis of sepsis, as defined by the Sepsis-3 criteria and exhibiting sepsis-induced hypoperfusion prior to the administration of adequate volume resuscitation:

  • hypotension requiring norepinephrine to maintain a mean arterial blood pressure (MAP) either predefined by the clinician or at 65 mm Hg or higher and/or

  • a serum lactate level >2 mmol/L (18mg/dL) and/or

  • acute oliguria defined as urine output <0.5mL/kg/hr and/or

  • mottled skin and/or

  • capillary refill time > 3 seconds.

Exclusion

Exclusion Criteria:

  • Administration of at least 1 L of IV fluid in the last 6 hours prior to screening.All crystalloids, colloids and blood products that the patient has received arecounted.

  • Known pregnancy.

  • Competing causes of lactic acidosis including: seizures within 3 hours ofenrollment, use of linezolid or metformin or anti-retrovirals at the time ofenrollment, carbon monoxide or cyanide poisoning, highly suspected or known ischemicbowel, and known mitochondrial disorders.

  • End-stage renal disease that requires chronic dialysis.

  • Concurrent haemorrhagic or obstructive shock.

  • Increased risk of fluid intolerance:

  • Echocardiographic evidence of moderate or severe left ventricular systolicdysfunction.

  • Echocardiographic evidence of moderate or severe right ventricular systolicdysfunction.

  • Hypoxemia index < 200 mmHg or sonographic evidence of bilateral B or C profile.

  • Abdominal compartment syndrome.

  • Post-cardiac arrest.

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: Ringer's Lactate
Phase:
Study Start date:
June 19, 2024
Estimated Completion Date:
July 30, 2025

Study Description

Adult patients admitted to the intensive care unit (ICU) with sepsis, as defined by the Sepsis-3 criteria, and exhibiting sepsis-induced hypoperfusion prior to receiving adequate volume resuscitation (i.e., 30 ml/kg of crystalloid), are administered Ringer's Lactate at a dose of 30 ml/kg. The initial 20 ml/kg is infused at a constant rate over the first 30 minutes, followed by a 30-minute pause, with an additional 10 ml/kg administered over the subsequent 15 minutes, completing the infusion within 75 minutes.

Up to 180 minutes post-infusion, no other fluids (e.g., gelatin, albumin) are administered except for antibiotics, sedatives, or vasoactive substances as needed. Ideally, only one catecholamine (e.g., norepinephrine) is administered. The volume and quantity of these substances are recorded. Arterial blood samples are collected for blood gas analysis, including hemoglobin levels. Urinary output is measured at 30, 60, and 180 minutes, and any blood loss, other than the 1.5 ml per sample collected, is quantified during hemoglobin monitoring. Additionally, urinary creatinine concentration is determined from urine samples collected at baseline.

The hemodilution data are utilized as input into a three-compartment model with microconstants for fluid redistribution and excretion.

Connect with a study center

  • Clinical Hospital Of Infectious Diseases "Dr. Victor Babes"

    Bucharest, București 030303
    Romania

    Active - Recruiting

  • Fundeni Clinical Institute

    Bucharest, București 022328
    Romania

    Active - Recruiting

  • "Prof CC Iliescu" Emergency Institue for Cardiovascular Diseases

    Bucharest, 022328
    Romania

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.